|
|
Active Org.- |
|
Active Indication- |
Inactive Indication- |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Phase 1/2 Study of RTX-240 Monotherapy and in Combination With Pembrolizumab
Open label, multicenter, multidose, first-in-human Phase 1/2 study of RTX-240 monotherapy or in combination of pembrolizumab for the treatment of patients with (1) relapsed/refractory R/R or locally advanced solid tumors (Phase 1/2) or (2) R/R Acute Myeloid Leukemia (AML) (Phase 1 only).
100 Clinical Results associated with 4-1BBL x IL15R
100 Translational Medicine associated with 4-1BBL x IL15R
0 Patents (Medical) associated with 4-1BBL x IL15R